- Conditions
- Cervicalgia, Low Back Pain
- Interventions
- Botulinum Toxins
- Drug
- Lead sponsor
- VA Connecticut Healthcare System
- Federal
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 15,996
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hodgkin's Disease
- Interventions
- Nivolumab, Brentuximab vedotin
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 20
- States / cities
- Duarte, California • Long Beach, California • Los Angeles, California + 16 more
- Conditions
- COPD
- Interventions
- OnabotulinumtoxinA, Placebo
- Drug · Other
- Lead sponsor
- RMW Testing
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Webster, Texas
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Belumosudil, Rituximab
- Drug
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Human Immunodeficiency Virus
- Interventions
- 3BNC117, 10-1074, Analytical treatment interruption
- Drug · Other
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- bevacizumab, erlotinib HCl, placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 4
- States / cities
- Vallejo, California • Athens, Georgia • Kansas City, Kansas + 1 more
- Conditions
- Myocarditis Acute, Cancer
- Interventions
- Abatacept plus, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 29
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 21 more
- Conditions
- Cardiovascular Disease
- Interventions
- N-acetylcysteine, Placebo
- Drug
- Lead sponsor
- Boston University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Brain Cancer, Choroid Plexus Tumors
- Interventions
- Carboplatin, Cisplatin, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Leucovorin, Methotrexate, Temozolomide, Vincristine
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Cancer, Giant Cell Tumors, Giant Cell Tumor of Bone, Benign Giant Cell Tumors
- Interventions
- Denosumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Stanford, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Lipodystrophy, Partial
- Interventions
- Tirzepatide, Usual care medications
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- PR104, docetaxel, Granulocyte colony-stimulating factor
- Drug
- Lead sponsor
- Proacta, Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 25
- States / cities
- San Diego, California • Miami, Florida • Chicago, Illinois + 22 more
- Conditions
- Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
- Interventions
- Insulin, Oral GW677954 Capsules (15 mg)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Beverly Hills, California
- Conditions
- Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
- Interventions
- L-citrulline, Plasmalyte A
- Drug
- Lead sponsor
- Asklepion Pharmaceuticals, LLC
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more
- Conditions
- Lateral Canthal Lines, Crow's Feet
- Interventions
- botulinum toxin, Type A, Vehicle
- Biological
- Lead sponsor
- Eirion Therapeutics Inc.
- Industry
- Eligibility
- 25 Years to 65 Years · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Miami, Florida • Pinellas Park, Florida • Louisville, Kentucky + 2 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms
- Interventions
- Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma
- Interventions
- Aldesleukin, Pembrolizumab
- Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Actinic Keratosis
- Interventions
- Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.
- Drug · Other · Device
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Fremont, California • Castle Rock, Colorado + 19 more
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
- Interventions
- Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
- Biological · Drug
- Lead sponsor
- Genelux Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 15
- States / cities
- Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more
- Conditions
- Psoriasis, Cardiovascular Disease
- Interventions
- Adalimumab
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 9
- States / cities
- Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more
- Conditions
- Type 2 Diabetes
- Interventions
- ITCA 650 (exenatide in DUROS)
- Drug
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Chandler, Arizona + 44 more
- Conditions
- Leukemia, Lymphoma, HIV
- Interventions
- Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine, Cyclophosphamide and Total Body Irradiation
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Duarte, California • San Francisco, California + 8 more
- Conditions
- Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
- Interventions
- Epcoritamab, Rituximab
- Drug
- Lead sponsor
- Reid Merryman, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • New York, New York • Rochester, New York + 2 more
- Conditions
- Type I Diabetes Mellitus
- Interventions
- Glutamine, Placebo
- Dietary Supplement
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 13 Years to 19 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida